
    
      Patients are randomized to receive blinded treatment with ZDV/3TC alone or in combination
      with 1592U89, orally for 16 weeks. If after the 16-week period certain criteria are met,
      patients may have the option to switch to open-label treatment for the remainder of the study
      period.
    
  